secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001213900-23-050029
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scott Brun, M.D., appointed to Jasper Board as R&D Committee Chair; Klein resigns
--------------------------------------------------------------------------------

- Scott Brun, M.D., appointed as Class I director effective June 20, 2023; chairs R&D Committee, serves on Compensation Committee.
- Dr. Brun has over 20 years pharma R&D leadership, including AbbVie, Abbott, and Horizon Therapeutics.
- Lawrence Klein, Ph.D., resigned effective June 20, 2023, due to his recent appointment as a Partner at Versant Ventures.
- Vishal Kapoor appointed to Audit and Compensation Committees.
- Dr. Brun receives initial option grant of 94,000 shares vesting over 4 years under Director Compensation Policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/0001213900-23-050029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023050029/ea180573-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-050029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer